2011 Scrip 100: Experimental collaboration model to drive Merck cancer research
This article was originally published in Scrip
In May 2010, Merck & Co launched an oncology collaborative trials network (Onconet) with leading international cancer research centres to speed up the development of its drug and vaccine candidates. The global research sites will lead the design and conduct of Phase 0 to Phase IIa clinical studies of Merck's investigational oncology candidates. Merck says that every year, the network will enrol approximately 1,200 patients in 30 to 40 clinical trials.
You may also be interested in...
The proceeds from the investment will enable Nyxoah to prepare for the IDE pivotal trial of the Genio system in the US, and accelerate market access and commercialization activities in Europe, Australia and New Zealand.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you would like to see in the format of the content or the method in which you receive and access Medtech Insight, or if you love it how it is, now is the time to have your voice heard.
Zimmer Biomet reported Q4 results that reflected solid progress in the company’s turnaround efforts, with knees leading the charge. But the company is making slower-than-expected progress resolving FDA warning letter issues and faces a new bribery lawsuit in Mexico.